Precipitated Withdrawal Fuels Buprenorphine Hesitancy, Survey Finds

Eighty-four percent of syringe service program clients who had ever tried buprenorphine reported experiencing precipitated withdrawal, and the severity of that reaction predicted how reluctant they were to try the medication again, according to a cross-sectional survey published October 28 in Substance Abuse Treatment, Prevention, and Policy. One hundred of the 148 clients surveyed reported the reaction, and those whose withdrawal was triggered while using fentanyl described it as more severe than clients using other opioids.

The study was led by O. Trent Hall of the Department of Psychiatry and Behavioral Health at Ohio State University's Wexner Medical Center. In the paper's acknowledgments Hall credits the staff of Equitas Health Safe Point, the syringe service program where clients with opioid use disorder were consecutively recruited.

What the survey measured

Participants answered questions about whether they had ever experienced precipitated withdrawal, how severe it was, and whether they would be willing to try buprenorphine again. Severity and reluctance were recorded on five-point scales.

The differences between groups were consistent. Clients who used fentanyl rated their worst precipitated withdrawal at a median of 4, described in the study's scale as "very severe," against a median of 3, "severe," for clients using other opioids (U = 419.5, z = −2.987, p = 0.003). Clients who had experienced the reaction were more reluctant to retry buprenorphine, with a median of 4, "agree," against 2, "disagree," for those who had not (U = 516.5, z = −2.649, p = 0.008). Across the sample, greater severity tracked with greater hesitancy in a partial correlation controlling for age, sex and race (rs(89) = 0.430, p < 0.001).

The authors conclude that precipitated withdrawal should be treated as a preventable adverse drug reaction, and that the experience is associated with reluctance to attempt the medication again. The paper is open access and was released in an early version that carries a permanent DOI while final copy-editing is completed.

Why the reaction happens, and why fentanyl made it worse

Buprenorphine is a partial agonist with high affinity for the mu-opioid receptor. As the paper's background section puts it, buprenorphine "may precipitate opioid withdrawal if administered too soon after another opioid": it displaces the opioid already bound to the receptor and drops the patient into withdrawal within minutes. Standard induction therefore asks patients to wait until they are already in moderate withdrawal. The survey's fentanyl finding is the part that bears on induction practice, because the clients who reported the most severe reactions were those using fentanyl rather than other opioids.

Clinicians have responded with low-dose induction, in which buprenorphine is introduced in small increments before withdrawal begins, and with high-dose initiation protocols that push through the transition. Our May report on hospital-based medication initiation practices described how those protocols are taught to prescribers working with fentanyl-exposed patients, and our October coverage of a Phase 2 trial for a non-opioid withdrawal treatment examined one experimental route around the same problem.

None of this makes buprenorphine optional. It reduces mortality in opioid use disorder, it can be prescribed in primary care without a separate federal waiver, and for many patients it is the most accessible form of medication-assisted treatment, particularly where a full opioid treatment program is a long drive away. The problem the Ohio State survey describes is not that the drug fails clinically. It is that a bad first experience travels by word of mouth through exactly the networks harm reduction programs depend on.

A preventable reaction with a communication problem

The people in this sample were not treatment-naive. They were connected to a syringe service program, which means they had access to naloxone, test strips and at least some contact with health care. If 84 percent of those who tried buprenorphine came away with a severe withdrawal memory, then the clinical failure happened at the point of induction, not at the point of referral.

The paper's framing points toward two fixes that do not require new molecules. The first is induction practice — ensuring that patients presenting with fentanyl exposure are started on protocols designed for it rather than on a timeline written for heroin. The second is expectation-setting and follow-up: a patient who is told that the transition may be uncomfortable but will be managed, and who has a clinician to call when it goes wrong, is less likely to conclude that the medication itself is the problem.

The survey also suggests a screening question worth adding to intake. Asking whether someone has tried buprenorphine before, and what happened, identifies the patients most likely to resist a second attempt and gives the prescriber a chance to explain what can be done differently.

What the design cannot tell you

The study is a single-site survey of 148 people, 92 men and 54 women, recruited at one syringe service program. Participants reported their own experiences, without clinical confirmation of the reaction, and answered from memory. The correlation between severity and hesitancy rests on 89 respondents rather than the full sample.

Because the survey is cross-sectional, it can show that severity and reluctance move together but not that one caused the other; people who were already skeptical of medication may also describe worse experiences. And the authors note that earlier research on whether precipitated withdrawal actually deters treatment has produced divergent results, which is the reason they designed this study around a specific population of people who inject drugs rather than a clinic sample.

What the study adds is a number that programs can use. Precipitated withdrawal is not a rare complication at the margins of buprenorphine induction. In this sample it was the common outcome, and the patients who experienced it most severely were the ones least likely to come back.